Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

BoA Keeps 'Buy' on Cytyc


Banc of America keeps buy on Cytyc (CYTC).

Analyst Kurt Kruger says Cytyc and its soon-to-be-acquired partner Digene Corp. receive a positive recommendation for approval for a test that should contribute significant revenue to Cytyc in 2003 and beyond. Encouraged by this recommendation, he thinks final approval could occur within six to nine months. Kruger raised the 2003 revenue estimate by $20 million, and raised the $0.95 EPS to $0.99. He says the path to significant revenues is by no means easy, but points out Cytyc did it once with its first liquid based Pap Smear, five years and $300 million ago. Kruger has a $28 target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus